13:37:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-26 Bokslutskommuniké 2024
2024-11-13 Kvartalsrapport 2024-Q3
2024-08-14 Kvartalsrapport 2024-Q2
2024-05-30 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2024-05-29 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-04-05 Extra Bolagsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-12-20 Extra Bolagsstämma 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-07-24 Kvartalsrapport 2023-Q2
2023-05-29 Årsstämma 2023
2023-05-16 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2023-05-08 Kvartalsrapport 2023-Q1
2023-02-15 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-16 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2022-05-13 Kvartalsrapport 2022-Q1
2022-05-13 Årsstämma 2022
2022-04-08 Extra Bolagsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-10 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2021-05-07 Årsstämma 2021
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-06-05 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2020-06-04 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-12-19 Extra Bolagsstämma 2019
2019-11-05 Kvartalsrapport 2019-Q3
2019-08-13 Kvartalsrapport 2019-Q2
2019-05-09 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2019-05-08 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-02-12 Bokslutskommuniké 2018
2018-11-20 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-07-25 Extra Bolagsstämma 2018
2018-05-09 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2018-05-08 Kvartalsrapport 2018-Q1
2018-05-08 Årsstämma 2018
2018-02-20 Bokslutskommuniké 2017
2017-11-21 Kvartalsrapport 2017-Q3
2017-08-22 Kvartalsrapport 2017-Q2
2017-05-11 Kvartalsrapport 2017-Q1
2017-05-11 Årsstämma 2017
2017-04-22 Bokslutskommuniké 2016
2016-11-11 Kvartalsrapport 2016-Q3
2016-09-21 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-18 Kvartalsrapport 2016-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHandel & varor
IndustriDagligvaror
Simris Group är ett bioteknikbolag. Bolaget är inriktat mot forskning och utveckling samt tillverkning av bioaktiva ämnen från odlade mikroalger, för tillämpningar inom nutrition, cosmeceuticals och läkemedel. Bolagets teknik ersätter även ohållbara råvaror från hotade arter och känsliga marina ekosystem. Första produkten är omega-3-tillskott som säljs under eget varumärke. Simris Group grundades 2011 och har sitt huvudkontor i Hammenhög.
2023-08-16 18:15:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

The preliminary outcome of the Rights Issue in Simris Group AB (publ) (“Simris Group” or the “Company”), the subscription period of which ended at 3:00 p.m. today, August 16, 2023, indicates that 51,341,938 new shares were subscribed for with and without support of subscription rights, corresponding to approximately 57 percent of the Rights Issue. The Rights Issue was fully secured through subscription commitments and underwriting agreements, and Simris Group will therefore receive the maximum amount of SEK 24,3m before issuance costs. Together with commitments associated with the Directed Issue previously announced by Simris, the Company will receive approximately SEK 40,5m before issuance costs.

The preliminary outcome indicates that approximately 55 percent of the Rights Issue was subscribed for with subscription rights, and approximately 2 percent without subscription rights. The Company will therefore utilise subscription commitments and underwriting agreements amounting to 43 percent of the Rights Issue.

The final outcome of the Rights Issue is expected to be announced on August 18, 2023. Shares will be allocated according to the principles set out in the information memorandum published on July 31, 2023. Information on allocation of shares subscribed for without support of subscription rights will be sent out to those who are allocated shares on August 18th, 2023, in the form of settlement notes.

The subscribed and allocated shares must be paid in cash according to the instructions on the settlement note. Shareholders registered with a nominee will be notified of their allocation in accordance with the nominee’s procedures. Only those who have been allotted shares will be notified. 

Simris Group will receive the maximum of SEK 24,3m from the Rights Issue and before issuance costs. Together with commitments associated with the Directed Issue previously announced by Simris, the Company will receive approximately SEK 40,5m before issuance costs.

Simris CEO, Julian Read commented, “considering the market conditions and summer vacation timing, the result of the Rights Issue is in-line with our cautious expectations. It was important that the Rights Issue was 100% secured so that investors could subscribe with a high level of confidence, knowing that the SEK 24,3m Rights Issue was guaranteed. We are grateful to existing shareholders that have demonstrated their continued support for Simris and we are delighted to have attracted significant new investors, with a commitment to the long-term and a specific interest in the field of Antibody Drug Conjugates. Now that the transaction has closed the Board and Management of the Simris Group will review the outcome considering the opportunities before us”.